Association of Vitamin D receptor gene BsmI polymorphism with type 2 diabetes mellitus in Pakistani population by Fatma, Hussain & Abdul, Sattar Naila
Association of  Vitamin D receptor gene BsmI polymorphism with type 
2 diabetes mellitus in Pakistani population
Hussain Fatma1, Sattar Naila Abdul2 
1. Department of  Biochemistry, Faculty of  Sciences, University of  Agriculture, Faisalabad, Pakistan. 
    Email:fatmauaf@yahoo.com
2. Department of  Biochemistry, Government College for Women University, Faisalabad, Pakistan. 
    Email: uaf_naila_sattar@yahoo.com
Abstract
Background: Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder with strong genetic components. The reported 
association of  vitamin D receptor (VDR) gene polymorphisms varies among ethnic groups.
Objectives: The present study was conducted to determine association of  vitamin D receptor gene BsmI (rs1544410 A>G) 
polymorphism with type 2 diabetes mellitus in Pakistani population.
Methods: Blood samples were collected from 150 T2DM patients and 100 non-diabetic engaged by convenient sampling 
method. After collection of  demographic data, assessment of  fasting glucose (FG), vitamin D, HbA1c, renal function tests, liver 
function tests and lipid profile was done. Candidate gene polymorphism was analyzed by DNA amplification with polymerase 
chain reaction and endonuclease digestion.
Results: Biochemical parameters were significantly different among case and control groups. Associations of  BsmI genotype 
with T2DM, related complications and biochemical variables were not significant. 
Conclusion: The current study did not provide evidence for the association of  VDR gene BsmI polymorphism with T2DM in 
Pakistani population.
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Introduction
Type 2 diabetes mellitus (T2DM) is a complex metabol-
ic disorder with strong genetic components. Candidate 
genes and variants for T2DM risk present in specific ge-
nome parts are involved in disease onset, associated path-
ways and functions.1,2
Single nucleotide polymorphisms (SNP) in vitamin D 
receptor (VDR) gene modulate glucose intolerance, in-
sulin secretion and sensitivity.3-5 Genetic polymorphism 
of  vitamin D receptor (VDR) gene can affect insulin se-
cretion, causing insulin resistance, affect vitamin D syn-
thesis, transportation and action.6 VDR gene located on 
chromosome 12q12-q14 mediates vitamin D action as it 
binds to vitamin D response elements (VDRE).7-9
Vitamin D binding protein (DBP) is the gene product that 
mediates vitamin D action. Cholcalciferol enters blood 
stream through binding to DBP. VDR gene genotype 
BsmI polymorphism found in intron 8is related with on-
set of  type 2 diabetes mellitus.10,11 Al-Daghri et al.12 stated 
that BsmI SNP is significantly more common in T2DM 
patients. Other reports also demonstrated analogous rela-
tionship between BsmI polymorphism and T2DM in dif-
ferent populations.13-16 Consequently, association between 
BsmI SNP and risk of  T2DM in different ethnic groups 
is not conclusive. 
SNP relates to disease susceptibility and response to treat-
ment.17 Hypovitaminosis D has been reported among Pa-
kistani population.18-20 However, researchers overlooked 
the role of  VDR gene SNP in local population especially 
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with reference to diabetes mellitus. Progress in identifica-
tion of  novel VDR gene variants predisposing to diabetes 
mellitus in Pakistan has been limited. Therefore, current 
research was conducted to assess the association of  VDR 




Study was conducted from March, 2015 to January, 2016 
at Clinico-Medical Biochemistry Lab., Department of  
Biochemistry, University of  Agriculture, Faisalabad, Pa-
kistan and Molecular Labs., Department of  Medical and 
Dentistry, Southmead Hospital, University of  Bristol, 
Bristol, United Kingdom. Sampling was conducted with-
in Pakistan and included consented 150 T2DM patients 
and 100 non-diabetic engaged by convenient sampling 
method. Graduates Studies and Research Board (GSRB), 
University of  Agriculture, Faisalabad, Pakistan granted 
ethical approval. 
Sample collection and bioassays
After collection of  demographic data,fasting blood sam-
ples were taken in EDTA-coated vacutainers.Assessment 
of  fasting glucose (FG), vitamin D, HbA1c, renal func-
tion tests,liver function tests and lipid profile was done by 
kits (Merck, Germany) as per manufacturer’s guidelines 
using Dade Behring clinical chemistry system(dimension 
auto-analyzer, Siemens, USA) and Diastat auto-analyzer 
(Randox, UK). 
DNA extraction and quantification
After genomic DNA extraction, the quantity and quali-
ty of  DNA was assessed by Nanodrop (Nanophotom-
eter™, Implen, Germany). Purity of  the DNA was as-
sessed by measuring optical density (OD) as OD260/
OD280.22
PCR-RFLP
Polymerase chain reaction (PCR) primers sequences used 
were: (F: CCCTGGCACTGACTCTGCTC; R: GGAAA-
CACCTTGCTTCTTCTCC) as described earlier.14,23 Go 
Taq kit (Promega Madison, Wisconsin USA) was used 
for about 1.0 mL of  genomic DNA (100 ng/ μL). PCR 
conditions were optimized for annealing temperature 
(60 °C) and Mg2+ concentration. The intron 8 was am-
plified to study the BsmI polymorphism(PCR thermocy-
cler T100TM, BioRad). Using RFLP (restriction fragment 
length polymorphism) method, fragments were digested 
to assess the BsmI (rs1544410 A>G) genotype (New En-
gland BioLabs®, R0109S). A molecular weight marker 
(HyperLadder II, Bioline or VC 100 bp Plus DNA Lad-
der, Vivantis) and for agarose gel visualization, UV light 
(UVITEC system, Uvitec Cambridge) were used.14
All data was expressed as mean ± SD (standard devi-
ation), % or n (number). Data analysis was performed 
using Statistical Package for Social Sciences (version 17; 




Results are presented in table l. Elevated FG, HbA1c, 
BMI, blood pressure and decreased vitamin D (P < 0.05) 
levels were evident in case group as compared to controls 
with negative correlation between vitamin D and HbA1c.
Liver function tests inferences were similar among both 
groups. Regarding RFTs and lipid profile, T2DM sam-
ple showed appreciably (P < 0.05) higher concentrations 
than control participants. Within the each group, asso-
ciations of  biochemical variables with vitamin D were 
negligible. Based upon the physician-diagnosed compli-
cations, diabetic subjects were sub-divided into CP (cardi-
ac patients), NP (nephropathy patients), RP (retinopathy 
patients) and HP (hypertensive patients). Among these 
groups, non-significant differences in clinical and bio-
chemical profiles were acquired, an observation that can 
be justified by the fact that most of  the patients were 
either in initial complication phases or were using oral hy-
poglycemic medications. Therefore, data was simplified 
and presented as case and control participants.
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BsmI polymorphisms  
After amplification of  intron 8 by PCR (figure 1a), het-
erozygosity of  intron 8 was confirmed by enzymatic di-
gestion (Figure 1b). Figure 1a-b showed typical results in 
current study that correlate with previously studied re-
sults. It was performed to check the action of  restriction 
enzyme. BsmI polymorphisms among T2DM complica-
tions groups were scored in figures 3-5. 
Three enzymatic digested fragments of  BsmI (76, 115 and 
191 bp) indicated heterozygosity (Bb) of  BsmI genotype. 
Differences of  BsmI genotypes of  VDR gene were signif-
icant between T2DM and normal groups (p < 0.01).  No 
substantial association was found between biochemical 
parameters and BsmI restriction site (p > 0.01). 
Table 1: Clinical and biochemical profile 
 
Parameters Diabetic  group (n = 150) 
Control group 
(n = 100) 
P value 
Clinical    
Age (years) 46.4 ± 3.5 46.8 ± 4.4 >0.05 
Gender  (Male/Female) 80/70 53/47 - 
BMI (kg/m2) 35.3 ± 10.7 22.9 ± 5.0 <0.05 
sBP (mm Hg) 149 ± 13 123 ± 12 <0.05 
dBP (mm Hg) 83 ± 7 75 ± 8 <0.05 
Biochemical    
FG (mg/dL) 144 ± 6.38 83 ± 5.21 <0.05 
HbA1c (%) 7.13 ± 0.58 4.46 ± 0.49 <0.05 
Vitamin D (mg/dL) 14.46 ± 1.29 23.87 ± 3.16 <0.05 
Liver Function Tests    
Total B (mg/dL) 1.02 ± 0.52 1.09 ± 0.39 0.53 
Direct B (mg/dL) 0.98 ± 0.36 0.93 ± 0.31 0.83 
ALT (mg/dL) 69.86 ± 14.67 71.88 ± 13.90 0.32 
AST (mg/dL) 34.54 ± 17.23 37.77 ± 18.01 0.29 
ALP (mg/dL) 51.87 ± 11.27 51.24 ± 11.05 0.99 
Renal Function Tests    
BUN (mg/dL) 39.57 ± 7.29 13.79 ± 5.71 <0.05 
Creatinine  (mg/dL) 2.18 ± 0.36 0.49 ± 0.40 <0.05 
Uric acid (mg/dL) 7.01 ± 0.88 3.00 ± 0.63 <0.05 
Lipid Profile    
Cholesterol (mg/dL) 276.38 ± 29.54 145.09 ± 12.87 <0.05 
LDL-C (mg/dL) 169.64 ± 11.37 65.52 ± 13.73 <0.05 
HDL-C (mg/dL) 37.41 ± 3.95 63.02 ± 13.26 <0.05 
TG (mg/dL) 453.05 ± 147.22 175.14 ± 8.02 <0.05 
          
          Data expressed as mean ± SD (standard deviation), % or n (number) unless otherwise indicated,  
          P<0.05: significant. BMI: body mass index, sBP: systolic blood pressure, dBP: diastolic blood pressure,  
          FG: fasting glucose, HbA1c: glycated hemoglobin, Total B: total bilirubin, Direct B: direct bilirubin,  
          ALT: alanine transaminase, AST: aspartate transaminase, ALP: alkaline phosphatase, BUN: blood  
          urea nitrogen, LDL-C: low density lipoprotein cholesterol, HDL-C: high density lipoprotein cholesterol,  
          TG: triglycerides       
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(a)                                                               (b) 
 
              Figure 1(a-b): a: Electrophoresis of a 2% agarose gel with intron 8 PCR product loaded;  
              1 – negative control; 2, 3 and 4 – intron 8 fragment with 191 bp. b: Electrophoresis of a 3% agarose gel    
               with BsmI enzymatic digestion of VDR intron 8; 5 – heterozygous Bb genotype (76, 115 and 191 bp);  
               6 – homozygous bb genotype (76 and 115 bp); 7 – homozygous BB genotype (191 bp) 
 
 
                                       Figure 2: VDR gene BsmIdigestion polymorphism products  
                                       (cardiac group & hypertensive patients) 
                                       Lane 11 have BB homozygous PCR-RFLP product. Lane 5,6,7,8,9,10,11& 12   
                                       have Bb heterozygous PCR-RFLP products. Lane 5 has bb homozygous  
                                       PCR-RFLP products of 175 bp. Lane 1 consist of ladder 100 bp. 
 
 
                                       Figure 2: VDR gene BsmIdigestion polymorphism products  
                                       (cardiac group & hypertensive patients) 
                                       Lane 11 have BB homozygous PCR-RFLP product. Lane 5,6,7,8,9,10,11& 12   
                                       have Bb heterozygous PCR-RFLP products. Lane 5 has bb homozygous  
                                       PCR-RFLP products of 175 bp. Lane 1 consist of ladder 100 bp. 
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Distribution of  genotype allele frequencies and carriage 
rate of  BsmI among diabetic patients, T2DM sub-groups 
and control group was non-significant (table 2). Effect 
of  VDR gene polymorphisms on metabolic parameters 
in terms of  probability to clarify their association under-
lying the diabetic complications are mentioned in table 
3. VDR gene BsmI polymorphism was related non-sig-
nificantly (p>0.05) to the diabetic complications in the 
present study.
 
                                  
                                 Figure 3: VDR gene BsmI digestion polymorphism products  
                                       (nephropathy patients group) 
                                        Lane  8 : ladder 100bp, lane; 1,3,5,6 and 7 have Bsm 
                                        Idigestion PCR-RFLP product BB 823 bp, lane ;1,3,5,6 and  
                                        7 consists 648 bp product Bb, lane 7 has bb product of 175 bp. 
 
 
                                Figure 4: VDR gene BsmIdigestion polymorphism products 
                                      (retinopathy patients group) 
                                      Lane M; Ladder of 100bp. Lane 3,5,8,9 & 10 consist  
                                      fragment BB of 823 bp. Lane 1,2,3,4,5,6,7,8,9 and 10  
                                      consist of Bb fragment of 648 bp. Lane 1,2,3,4,5,6,7,8,9  
                                      and 10 consist of fragment bb of 175 bp.  
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Table 2: Distribution of genotype allele frequencies and carriage rate of BsmI 
 
Groups Genotypes Total 
bb Bb BB 
Control 2 64 34 100 
2.0% 64.0% 34.0% 100.0% 
Diabetic  4 119 27 150 
2.7% 79.3% 18.0% 100.0% 
CP 3 59 18 80 
3.8% 73.8% 22.5% 100.0% 
NP 0 18 2 20 
0.0% 90.0% 10.0% 100.0% 
RP 0 19 1 20 
0.0% 95.0% 5.0% 100.0% 
HP 1 23 6 30 
3.3% 76.7% 20.0% 100.0% 
Total 6 183 61 250 
2.4% 73.2% 24.4% 100.0% 
           Data expressed as X2= 15.08S, p< 0.05, S: significant (diabetic & control groups); X2 = 13.158NS,   p=0.108    
           (diabetic subgroups and control groups). 
           CP: cardiac patients, NP: nephropathy patients, RP: retinopathy patients, HP: hypertensive patients, NS:  
           non-significant 
Table 3: Probability values for the association of biochemical  
parameters and BsmIgenotypes 
 
                      T2DM Sub-groups 
 
Parameters Control CP NP RP HP 
 
HbA1c 0.775 0.597 0.436 0.256 0.376 
Vitamin-D 0.334 0.592 0.165 0.858 0.279 
T. bilirubin 0.810 0.999 0.263 0.601 0.585 
D. bilirubin 0.850 0.871 0.841 0.037 0.495 
ALT 0.229 0.064 0.694 0.051 0.595 
AST 0.399 0.291 0.131 0.577 0.870 
ALP 0.138 0.180 0.136 0.334 0.622 
BUN 0.257 0.855 0.205 0.403 0.123 
Creatinine 0.536 0.137 0.620 0.868 0.658 
Uric acid 0.336 0.989 0.426 0.422 0.717 
Cholesterol 0.335 0.750 0.633 0.966 0.628 
LDL-C 0.563 0.358 0.782 0.641 0.369 
HDL-C 0.763 0.988 0.178 0.954 0.719 
TG 0.206 0.629 0.562 0.914 0.969 
     
    Data expressed as p – value  
    CP: cardiac patients, NP: nephropathy patients, RP: retinopathy patients, HP: hypertensive patients, HbA1c:     
    glycated hemoglobin, T. bilirubin: total bilirubin, D. bilirubin: direct bilirubin, ALT: alanine transaminase, AST:    
    aspartate transaminase, ALP: alkaline phosphatase, BUN: blood urea nitrogen, LDL-C: low density lipoprotein    
    cholesterol, HDL-C: high density lipoprotein cholesterol, TG: triglycerides      
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Discussion
Although numerous genes have role in T2DM,24,25 VDR 
gene plays a dominant role in onset and progression of  
T2DM.11,14,26 BsmI polymorphism found in intron 8 of  
VDR gene may be involved in pathogenesis of  T2DM.27
Prevalence of  vitamin D deficiency in T2DM group was 
higher as compared to control subjects, showing signifi-
cant association of  BsmI with T2DM in the present study. 
However, Santos et al.27 observed conflicting results 
in Brazilian population. Contrary to current findings, 
Dilmec et al.14 found significant association of  BsmI to 
T2DM onset. While Israni et al.28 suggested potential role 
of  BsmI polymorphisms. Wang et al.30 studied significant 
association of  BsmI polymorphism with T2DM onset. 
Review of  literature indicates conflicting results regard-
ing the impact of  VDR gene polymorphisms on T2DM 
pathogenesis in different populations14,26,30 either sup-
porting or contrasting current findings. Heterogeneity in 
different populations and limited knowledge of  underly-
ing mechanism may be responsible for these discrepan-
cies.31,32
Statistically non-significant relationship between BsmI 
polymorphism and T2DM in current project is support-
ed by earlier study.33 This study suggests that the BsmI 
may be related with susceptibility to T2DM subjects but 
genetic contribution of  VDR gene polymorphism for 
the development or existing diabetic complications is not 
clear. In addition, vitamin D receptor gene consists of  
many single nucleotide polymorphisms (SNPs). To inves-
tigate whether functional changes of  VDR gene may be 
potential risk for T2DM, future studies should focus on 
population or case-control studies along with family link-
age with multiple SNP study.34
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